PolyQ-expanded Ataxin-3 Interacts with Full-length Ataxin-3 in a PolyQ Length-dependent Manner

Overview

Journal Neurosci Bull

Specialty Neurology

Date 2008 Aug 1

PMID 18668148

Citations 4

Authors

Na-Li Jia

Er-Kang Fei

Zheng Ying

Hong-Feng Wang

Guang-Hui Wang

Affiliations

Soon will be listed here.

Abstract

Objective: Machado-Joseph disease (MJD), also known as spinocerebellar ataxia type 3 (SCA3), is a dominant neurodegenerative disorder caused by an expansion of the polyglutamine (polyQ) tract in MJD-1 gene product, ataxin-3 (AT3). This disease is characterized by the formation of intraneuronal inclusions, but the mechanism underlying their formation is still poorly understood. The present study is to explore the relationship between wild type (WT) AT3 and polyQ expanded AT3.

Methods: Mouse neuroblastoma (N2a) cells or HEK293 cells were co-transfected with WT AT3 and different truncated forms of expanded AT3. The expressions of WT AT3 and the truncated forms of expanded AT3 were detected by Western blotting, and observed by an inverted fluorescent microscope. The interactions between AT3 and different truncated forms of expanded AT3 were detected by immunoprecipitation and GST pull-down assays.

Results: Using fluorescent microscope, we observed that the truncated forms of expanded AT3 aggregate in transfected cells, and the full-length WT AT3 is recruited onto the aggregates. However, no aggregates were observed in cells transfected with the truncated forms of WT AT3. Immunoprecipitation and GST pull-down analyses indicate that WT AT3 interacts with the truncated AT3 in a polyQ length-dependent manner.

Conclusion: WT AT3 deposits in the aggregation that was formed by polyQ expanded AT3, which suggests that the formation of AT3 aggregation may affect the normal function of WT AT3 and increase polyQ protein toxicity in MJD.

Citing Articles

PolyQ-expanded proteins impair cellular proteostasis of ataxin-3 through sequestering the co-chaperone HSJ1 into aggregates.

Yue H, Hong J, Zhang S, Jiang L, Hu H Sci Rep. 2021; 11(1):7815.

PMID: 33837238 PMC: 8035147. DOI: 10.1038/s41598-021-87382-w.

Normal ATXN3 Allele but Not CHIP Polymorphisms Modulates Age at Onset in Machado-Joseph Disease.

Franca Jr M, Emmel V, DAbreu A, Maurer-Morelli C, Secolin R, Bonadia L Front Neurol. 2012; 3:164.

PMID: 23181052 PMC: 3500826. DOI: 10.3389/fneur.2012.00164.

Mouse ataxin-3 functional knock-out model.

Switonski P, Fiszer A, Kazmierska K, Kurpisz M, Krzyzosiak W, Figiel M Neuromolecular Med. 2010; 13(1):54-65.

PMID: 20945165 PMC: 3044828. DOI: 10.1007/s12017-010-8137-3.

Current understanding on the pathogenesis of polyglutamine diseases.

He X, Lin F, Qin Z Neurosci Bull. 2010; 26(3):247-56.

PMID: 20502504 PMC: 5552486. DOI: 10.1007/s12264-010-0113-2.

References

Evert B, Araujo J, Vieira-Saecker A, de Vos R, Harendza S, Klockgether T . Ataxin-3 represses transcription via chromatin binding, interaction with histone deacetylase 3, and histone deacetylation. J Neurosci. 2006; 26(44):11474-86. PMC: 6674535. DOI: 10.1523/JNEUROSCI.2053-06.2006. View

Zoghbi H, Orr H . Polyglutamine diseases: protein cleavage and aggregation. Curr Opin Neurobiol. 1999; 9(5):566-70. DOI: 10.1016/S0959-4388(99)00013-6. View

Busch A, Engemann S, Lurz R, Okazawa H, Lehrach H, Wanker E . Mutant huntingtin promotes the fibrillogenesis of wild-type huntingtin: a potential mechanism for loss of huntingtin function in Huntington's disease. J Biol Chem. 2003; 278(42):41452-61. DOI: 10.1074/jbc.M303354200. View

Burnett B, Pittman R . The polyglutamine neurodegenerative protein ataxin 3 regulates aggresome formation. Proc Natl Acad Sci U S A. 2005; 102(12):4330-5. PMC: 555481. DOI: 10.1073/pnas.0407252102. View

Iuchi S, Hoffner G, Verbeke P, Djian P, Green H . Oligomeric and polymeric aggregates formed by proteins containing expanded polyglutamine. Proc Natl Acad Sci U S A. 2003; 100(5):2409-14. PMC: 151354. DOI: 10.1073/pnas.0437660100. View

Paulson H, Das S, Crino P, Perez M, Patel S, Gotsdiner D . Machado-Joseph disease gene product is a cytoplasmic protein widely expressed in brain. Ann Neurol. 1997; 41(4):453-62. DOI: 10.1002/ana.410410408. View

Wang G, Ide K, Nukina N, Goto J, Ichikawa Y, Uchida K . Machado-Joseph disease gene product identified in lymphocytes and brain. Biochem Biophys Res Commun. 1997; 233(2):476-9. DOI: 10.1006/bbrc.1997.6484. View

Gusella J, Macdonald M . Molecular genetics: unmasking polyglutamine triggers in neurodegenerative disease. Nat Rev Neurosci. 2001; 1(2):109-15. DOI: 10.1038/35039051. View

Li F, Macfarlan T, Pittman R, Chakravarti D . Ataxin-3 is a histone-binding protein with two independent transcriptional corepressor activities. J Biol Chem. 2002; 277(47):45004-12. DOI: 10.1074/jbc.M205259200. View

10.

Ellisdon A, Thomas B, Bottomley S . The two-stage pathway of ataxin-3 fibrillogenesis involves a polyglutamine-independent step. J Biol Chem. 2006; 281(25):16888-16896. DOI: 10.1074/jbc.M601470200. View

11.

Fei E, Jia N, Zhang T, Ma X, Wang H, Liu C . Phosphorylation of ataxin-3 by glycogen synthase kinase 3beta at serine 256 regulates the aggregation of ataxin-3. Biochem Biophys Res Commun. 2007; 357(2):487-92. DOI: 10.1016/j.bbrc.2007.03.160. View

12.

Haacke A, Broadley S, Boteva R, Tzvetkov N, Hartl F, Breuer P . Proteolytic cleavage of polyglutamine-expanded ataxin-3 is critical for aggregation and sequestration of non-expanded ataxin-3. Hum Mol Genet. 2006; 15(4):555-68. DOI: 10.1093/hmg/ddi472. View

13.

Nishiyama K, Murayama S, Goto J, Watanabe M, Hashida H, Katayama S . Regional and cellular expression of the Machado-Joseph disease gene in brains of normal and affected individuals. Ann Neurol. 1996; 40(5):776-81. DOI: 10.1002/ana.410400514. View

14.

Wang G, Sawai N, Kotliarova S, Kanazawa I, Nukina N . Ataxin-3, the MJD1 gene product, interacts with the two human homologs of yeast DNA repair protein RAD23, HHR23A and HHR23B. Hum Mol Genet. 2000; 9(12):1795-803. DOI: 10.1093/hmg/9.12.1795. View

15.

Tam S, Geller R, Spiess C, Frydman J . The chaperonin TRiC controls polyglutamine aggregation and toxicity through subunit-specific interactions. Nat Cell Biol. 2006; 8(10):1155-62. PMC: 2829982. DOI: 10.1038/ncb1477. View

16.

Bevivino A, Loll P . An expanded glutamine repeat destabilizes native ataxin-3 structure and mediates formation of parallel beta -fibrils. Proc Natl Acad Sci U S A. 2001; 98(21):11955-60. PMC: 59749. DOI: 10.1073/pnas.211305198. View

17.

Paulson H, Perez M, Trottier Y, Trojanowski J, Subramony S, Das S . Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3. Neuron. 1997; 19(2):333-44. DOI: 10.1016/s0896-6273(00)80943-5. View

18.

Evert B, Vogt I, Vieira-Saecker A, Ozimek L, de Vos R, Brunt E . Gene expression profiling in ataxin-3 expressing cell lines reveals distinct effects of normal and mutant ataxin-3. J Neuropathol Exp Neurol. 2003; 62(10):1006-18. DOI: 10.1093/jnen/62.10.1006. View

19.

Yang W, Dunlap J, Andrews R, Wetzel R . Aggregated polyglutamine peptides delivered to nuclei are toxic to mammalian cells. Hum Mol Genet. 2002; 11(23):2905-17. DOI: 10.1093/hmg/11.23.2905. View

20.

Tanaka M, Machida Y, Nishikawa Y, Akagi T, Hashikawa T, Fujisawa T . Expansion of polyglutamine induces the formation of quasi-aggregate in the early stage of protein fibrillization. J Biol Chem. 2003; 278(36):34717-24. DOI: 10.1074/jbc.M209852200. View